Reaction equation
[CH3:1][O:2][C:3]1[CH:8]=[C:7]([CH3:9])[C:6]([S:10]([N:13]([CH2:15][C:16]2[O:20][CH:19]=[C:18]([C:21]([OH:23])=O)[CH:17]=2)[CH3:14])(=[O:12])=[O:11])=[C:5]([CH3:24])[CH:4]=1.C1N=CN(C(N2C=NC=C2)=O)C=1.[N:37]1[CH:42]=[CH:41][C:40]([CH2:43][N:44]2[CH2:49][CH2:48][NH:47][CH2:46][CH2:45]2)=[CH:39][CH:38]=1>ClCCCl>[CH3:1][O:2][C:3]1[CH:4]=[C:5]([CH3:24])[C:6]([S:10]([N:13]([CH3:14])[CH2:15][C:16]2[O:20][CH:19]=[C:18]([C:21]([N:47]3[CH2:48][CH2:49][N:44]([CH2:43][C:40]4[CH:39]=[CH:38][N:37]=[CH:42][CH:41]=4)[CH2:45][CH2:46]3)=[O:23])[CH:17]=2)(=[O:11])=[O:12])=[C:7]([CH3:9])[CH:8]=1Participants
5
Procedure
The title compound was prepared according to general procedure AA using 5-({[(4-Methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino}methyl)furan-3-carboxylic acid (63 mg, 0.18 mmol), CDI (58 mg, 0.36 mmol) and 1-(pyridin-4-ylmethyl)piperazine (53 mg, 0.30 mmol) in DCE (4.5 mL).
Sources & evidence
- ORD record
- ord-ea06cb87c58240c199dade3a8bd6336a
- Source dataset
- uspto-grants-2014_01
- Patent number
- US08623859B2
Linked notes
Loading…